Follow us on Twitter
twitter icon@FreshPatents


Antibodies patents

      

This page is updated frequently with new Antibodies-related patent applications.




 Antibodies to disulfated heparin disaccharide in the diagnosis of neuropathy patent thumbnailnew patent Antibodies to disulfated heparin disaccharide in the diagnosis of neuropathy
Methods aiding in the diagnosis of certain neuropathies are disclosed, in which the titer of antibodies to a disulfated heparin disaccharide is assessed in a test sample from a subject. Also disclosed are apparatus and kits that can be used in the methods of the invention..
Washington University


 Mitochondrial preproteins as markers for alzheimer's disease patent thumbnailnew patent Mitochondrial preproteins as markers for alzheimer's disease
The present invention is inter alia concerned with a method of diagnosing alzheimer's disease in a patient, wherein said method is based on determining the amount of at least one premature mitochondrial protein. Further, the present invention relates to the use of such a protein as marker for alzheimer's disease.
Albert-ludwigs-universitat Freiburg


 A-fucosylation detection in antibodies patent thumbnailnew patent A-fucosylation detection in antibodies
This invention describes a new analytical method to determine the quantity and distribution of fucose per fc within an antibody preparation.. .
Roche Glycart Ag


 Foxc1 antibodies and methods of their use patent thumbnailnew patent Foxc1 antibodies and methods of their use
In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human foxc1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer.
John Wayne Cancer Institute


 E1 enzyme mutants and uses thereof patent thumbnailnew patent E1 enzyme mutants and uses thereof
The invention provides isolated nucleic acids molecules, designated uba3, uae, or uba6, or other e1 enzyme variant nucleic acid molecules, which encode novel e1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing uba3, uae, or uba6, or other e1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a uba3, uae, or uba6, or other e1 enzyme variant gene has been introduced or disrupted.
Millennium Pharmaceuticals, Inc.


 Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers patent thumbnailnew patent Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
The present invention relates to in vitro methods for the diagnosis of chronic obstructive pulmonary disease (copd), wherein the expression of the marker gene dmbt1 is determined. In particular, the invention relates to an in vitro diagnostic method of assessing the susceptibility of a subject to develop progressive copd involving the appearance of irreversible lung damage, wherein the expression of the marker gene dmbt1 and optionally one or more further marker genes selected from kiaa1199, tmsb15a, dpp6, slc51b, nudt11, elf5, azgp1, prrx1, aqp3, sfn, gpr110, gdf15, rasgrf2, rnd1, pla1a, fgg, ceacam5, hyal2, ahrr, cxcl3, cyp1a1, cyp1b1, cyp1a2, cst6, ntrk2, comp, itga10, cthrc1, tal1, fibin, bex5, bex1, esm1 and ghrl is determined.
Transgenion-international Institute For Regenerative Translation Medicine Gmbh


 Cell culture process for producing a protein patent thumbnailnew patent Cell culture process for producing a protein
The invention provides the mammalian cell culture process for the production of monoclonal antibodies and fusion proteins wherein the mammalian cell is cultured in suitable cell culture conditions specifically maintaining monophasic temperature.. .
Lupin Limited


 Method for preparing antibody through regulation of sugar content of antibody patent thumbnailnew patent Method for preparing antibody through regulation of sugar content of antibody
Provided are a method of preparing an antibody with a regulated, sugar chain content, the method including the step of culturing antibody-expressing cells in a medium including glycerol as an additive for regulating the antibody sugar chain content, a method of preparing a high-quality population of antibodies by regulating the sugar content of the antibody to a desired content, and a population of antibodies prepared by the method. Further, provided is a method of regulating the antibody sugar chain content, the method including the step of culturing antibody-expressing cells in a medium including glycerol as an additive for regulating the antibody sugar chain content.
Prestige Biopharma Pte. Ltd.


 Surface display of whole antibodies in eukaryotes patent thumbnailnew patent Surface display of whole antibodies in eukaryotes
Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest..
Merck Sharp & Dohme Corp.


 Human lambda light chain mice patent thumbnailnew patent Human lambda light chain mice
Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.


new patent

Stabilized single domain antibodies

The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising vhhs in biological circulatory systems..
Ablynx N.v.

new patent

Anti-vasa antibodies, and methods of production and use thereof

Anti-vasa antibodies (mabs), particularly humanized mabs that specifically bind to vasa with high affinity, are disclosed. The amino acid sequences of the cdrs of the light chains and the heavy chains, as well as consensus sequences for these cdrs, of these anti-vasa mabs are provided.
Ovascience, Inc.

new patent

Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Isolated monoclonal antibodies that bind to specific epitopes of human tissue factor pathway inhibitor (tfpi) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-tfpi monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided..
Bayer Healthcare Llc

new patent

Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof

Disclosed herein are antibodies which specifically bind to at least one epitope defined by the immunogenic glycopeptide. Other aspects of the present disclosure are pharmaceutical composition comprising the antibody; and method for preventing and/or treating globo-h-positive cancer..
Mackay Medical Foundation The Presbyterian Church

new patent

Neutralizing antibodies and methods of use thereof

This invention provides monoclonal antibodies that recognize the toll-like receptor 4/md-2 receptor complex, and monoclonal antibodies that recognize the tlr4/md2 complex as well as tlr4 when not complexed with md-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics.
Novimmune Sa

new patent

Combination therapies with anti-cd38 antibodies

The present invention relates to combination therapies with anti-cd38 antibodies and all-trans retinoic acid.. .
Janssen Biotech, Inc.

new patent

Anti-cd14 antibodies and uses thereof

The present invention relates to chimeric anti-cd14 antibodies and methods of using the same. In some embodiments, the present invention relates to the use of chimieric anti-cd 14 antibodies in research, diagnostic, and therapeutic applications.
University Of Oslo

new patent

Antagonists for abdominal vasopressin v2 receptor and uses thereof

Provided herein are antagonists or binding agents of an abnormal vasopressin receptor v2 (e.g., abnv2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor v2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro.
Woomera Therapeutics, Inc

new patent

Anti-axl antibodies

antibodies which specifically bind to the ax i protein are described. Also disclosed are methods for the production and use of the anti-axl antibodies..
Bergenbio As

new patent

Intracellular delivery compounds

Pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the intracellular delivery of antibodies.. .

new patent

Dual receptor antagonistic antigen-binding proteins and uses thereof

This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases.
Amgen Inc.

new patent

Methods of using anti-pd-l1 antibodies and their use to enhance t-cell function to treat tumor immunity

The present application relates to anti-pd-l1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance t-cell function to upregulate cell-mediated immune responses and for the treatment of t cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.. .
Genentech, Inc.

new patent

Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics

This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against krtcap3, fam26f, mgc52498, fam70a or tmem154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages.
Compugen Ltd

new patent

Provasopressin antagonists and uses thereof

Provided herein are pro-vp antagonists, such as antibodies and antigen-binding portions thereof specific for pro-vp, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples.
Woomera Therapeutics, Inc.

new patent

Ang2-binding molecules

Ang2-binding molecules, preferably ang2-binding immunoglobulin single variable domains like vhhs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with ang2-mediated effects on angiogenesis. Nucleic acids encoding ang2-binding molecules, host cells and methods for preparing same..
Boehringer Ingelheim International Gmbh

new patent

Antibodies to hgf and compositions containing

The present invention is directed to antibodies and fragments thereof having binding specificity for hgf. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the vh, vl and cdr polypeptides described herein, and the polynucleotides encoding them.
Alderbio Holdings Llc

new patent

Heavy chain only antibodies to ang-2

Disclosed herein are monospecific hcab antibodies with antigen-binding specificity to ang-2 and bispecific antibodies with antigen-binding specificities to ang-2 and vegf or pdgf.. .
Allergan, Inc.

new patent

Antibodies to tau and uses thereof

Monoclonal antibodies to human tau aggregate, compositions comprising such tau antibodies, and methods of using such tau antibodies for the treatment of neurodegenerative diseases including alzheimer's disease, progressive supranuclear palsy and pick's disease.. .
Eli Lilly And Company

new patent

Methods of modulating inflammasome activity to treat inflammatory conditions

Compositions and methods for reducing inflammation in the central nervous system (cns) of a mammal that has been subjected to a stroke, traumatic injury to the cns such as traumatic brain injury (tbi), spinal cord injury (sci), or having an autoimmune or cns disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., asc, nalp1) in a mammalian inflammasome (e.g., the nalp1 inflammasome) and have use as treatments for sci, tbi, stroke, and autoimmune and cns diseases in a mammal.
University Of Miami

new patent

Enantiopure haptens for nicotine vaccine development

The invention provides chiral haptens (−)-3′-amnic and (−)-n4n for use in generating antibodies in a patient specific for (−)-nicotine. The haptens can be conjugated to suitable carrier proteins and administered as an antigenic mixture, optionally comprising adjuvant(s), to a patient suffering from nicotine or tobacco addiction or habituation..
The Scripps Research Institute

new patent

Sperm-specific cation channel, and uses therefor

Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (catsper1) are disclosed. The catsper1 protein is shown to be specifically expressed in sperm and to be necessary for sperm motility.
Children's Medical Center Corporation

new patent

Antibody drug conjugates

The present invention relates to anti-fgfr2 and fgfr4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.. .
Novartis Ag

new patent

Compositions comprising anti-cd38 antibodies and carfilzomib

Disclosed herein are compositions and kits which comprise anti-cd38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits..
The Regents Of The University Of California

new patent

Liposome-peptide conjugate and using same to induce production of anti-hiv antibodies

The present invention relates, in general, to human immunodeficiency virus (hiv), and, in particular, to a method of inducing neutralizing antibodies to hiv and to compounds and compositions suitable for use in such a method.. .
Duke University

new patent

Multi-component-multistage malaria vaccines

The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different plasmodium falciparum antigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans.
Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

new patent

Methods of inhibiting platelet aggregation and preventing thrombosis using antibodies that bind (na++k+)-atpase beta subunit

Methods of inhibiting platelet activation and aggregation using peptide vaccine or antibodies that have binding specificity for the β subunit of the (na++k+)-atpase are provided, along with methods for inhibiting or preventing thrombosis in a subject using such peptide vaccine or antibodies.. .

new patent

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited

Antibody-based affinity reagents for binding paclitaxel

The disclosure is directed to optimized affinity reagent compositions, such as antibodies, antibody fragments, and antibody derivatives, for binding paclitaxel, and related methods of use.. .
Autotelic Llc

Assay for diagnosing streptococcus pneumoniae

Assays for detecting anti-streptococcal antibodies in biological samples using one or more streptococcal antigens are described herein. Various combinations of antigens may be used in the assays.
Sanofi Pasteur Limited

Two-dimensional material-based field-effect transistor sensors

Atomically layered transition metal dichalcogenides (tmdcs) exhibit a significant potential to enable low-cost transistor biosensors that permit single-molecule-level quantification of biomolecules. Two different principles for operating such biosensors are presented.
The Regents Of The University Of Michigan

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited

Antibodies specific for 4,6-diamino-5-(formylamino)pyrimidine and uses thereof

The invention includes monoclonal and polyclonal antibodies, and antigen-binding fragments thereof, having specific binding affinity for 4,6-diamino-5-(formylamino)pyrimidine (fapy-adenine); hybridomas producing such antibodies; immunoconjugates comprising an antibody or antigen-binding fragment of the invention coupled to a moiety; and in vitro and in vivo methods for using such antibodies, antibody fragments, and conjugates based on binding to fapy-adenine; nucleic acids encoding the heavy and/or light chains of the antibodies; vectors comprising the nucleic acid sequences encoding the heavy and/or light chains; host cells comprising and, optionally, expressing the nucleic acid sequences; and methods for the production of the aforementioned materials.. .
Florida State University Research Foundation, Inc.

Antigen-binding proteins that activate the leptin receptor

The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (lepr), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind lepr and activate lepr signaling.
Regeneron Pharmaceuticals, Inc.

Bispecific egfr/c-met antibodies

Bispecific egfr/c-met antibodies and methods of making and using the molecules.. .
Janssen Biotech, Inc.

Synthetic antibody mimic peptides

The present disclosure relates to compositions and methods comprising peptide molecules that mimic the binding and functional properties of native antibodies relative to their respective targets. Some embodiments comprise peptide-drug conjugates (pdcs) comprising the mimic peptides disclosed herein.
Formurex, Inc.

Anti-wt1/hla-specific antibodies

The present invention relates to antibodies or fragments thereof binding to human wt1/hla. In particular, the present invention relates to antibodies or fragments thereof that have combined improved and/or beneficial properties, and are therefore suited for clinical development..
Immatics Biotechnologies Gmbh

Anti-lag3 antibodies and uses thereof

The present invention provides antibodies that bind to the t cell co-inhibitor lymphocyte activation gene 3 (lag3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to lag3.
Regeneron Pharmaceuticals, Inc.

Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasus arteritis

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (pmr) or takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.. .
Prothena Biosciences Limited

Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases

The present invention provides human anti-il-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to il-6 and that has an extended in vivo half-life for the treatment and prevention of il-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors..
Medimmune Limited

Anti-blys antibodies

The present invention provides antibodies and antigen-binding fragments thereof that bind specifically to blys, immunoglobulin chains thereof, variants thereof; and method of use thereof, e.g., for the treatment or prevention of inflammatory and/or immune diseases such as systemic lupus erythramatous; as well as polynucleotides encoding the immunoglobulin chains of such antibodies and fragments. Methods for the recombinant expression of immunoglobulin chains are also part of the present invention..

Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof

The present invention provides antibodies or the antigen-binding portion thereof to a tumor-associate carbohydrate antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof.
Obi Pharma, Inc.

Transgenic animals capable of producing humanized ige at much higher levels than mouse ige

The transgenic non-human animals are constructed, in whose genome the coding sequences of one of the animal's endogenous immunoglobulin cγ constant regions are replaced by human immunoglobulin cε constant region coding sequences. The transgenic animal is mouse, in whose genome the cγ1 constant regions are replaced by the human immunoglobulin cε constant regions and the cκ constant region is replaced by the human immunoglobulin cκ constant region.
Allermabs Co. Ltd.

Modulating gamma-c-cytokine activity

Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

Toxin genes and methods for their use

Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided.
Athenix Corporation

Chemical and biochemical adducts as biomarkers for organophosphate exposure

Provided are methods for identifying op-adducted biomarkers of op exposure as well as compounds containing ops that can provide op adducts and compounds of formula 1 for eliciting antibodies that specifically and selectively bind to the op adducts, wherein the formula 1 compounds have the structure of op-peptide-linker-cp, wherein cp is a carrier protein, op represents a structure corresponding to that of a reactive organic phosphorous compound covalently modifying a tyrosine residue hydroxyl group of the peptide of formula i and the other variable groups are as described herein.. .
Human Biomolecular Research Foundation



Antibodies topics:
  • Antibodies
  • Recombinant
  • Nucleic Acid
  • Nucleic Acids
  • Polypeptide
  • Therapeutics
  • Immunoglobulin
  • Immunoglobulins
  • Monoclonal
  • Radiation Therapy
  • Desmoplastic
  • Hypertension
  • Hypertensive
  • Immunotherapy
  • Photodynamic Therapy


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.3638

    file did exist - 2680

    2 - 1 - 58